Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.67, 1.49]
2 studies · 106 participants
Low

COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes leaving the study early ‐ Any reason compared with CLOZAPINE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.41 [0.46, 4.29]
3 studies · 240 participants
Very low

FLUPHENAZINE (ORAL) vs AMISULPRIDE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.19 [0.63, 2.28]
2 studies · 98 participants
Very low